Executive Vice President, North America Commercial Operations
Cynthia has spent her entire career in the healthcare industry. Prior to joining in February 2014, she held a variety of COO roles for various biotech and specialty companies.
Cynthia has over 30 years of senior healthcare experience in the fields of pharmaceuticals, biotechnology and medical devices.
As President of Ipsen North America, she leads all commercial operations for the U.S. and Canada, and manages shared services for Ipsen research facility in Cambridge, MA. Previously, she served as Chief Operating Officer of Eisai Inc. She joined Eisai in 2008 from Amgen Inc. where she served as a Vice President and General Manager of the Oncology Business Unit of Amgen Inc. since May 2005. She also served on Amgen's Senior Management Team responsible for talent development in medical affairs, drug development, regulatory, health economic and commercial functions.
Cynthia started her corporate career at Johnson and Johnson (J&J) with Janssen Pharmaceutica, a division of J&J, where she held multiple commercial roles over an eighteen year period, including her role as General Manager of Ortho Biotech UK & Ireland, a J&J biotech company.
Cynthia currently serves on the Harvard JFK School Women’s Leadership Board.
Cynthia is a graduate of the Executive MBA program at the Wharton School of Business, University of Pennsylvania. Her undergraduate degree, a Bachelor of Science in Nursing, was completed at the University of Delaware.
Vice President, Franchise Head – Endocrinology / Oncology
Paul has over 20 years of experience working in the biotechnology industry. Most recently, Paul was a management consultant helping clients launch injectable medications across a variety of therapeutic categories, including Oncology. Notably, Paul worked with Ipsen prior to his appointment to the position of Vice President and General Manager for Oncology and Endocrinology, guiding strategy for its Oncology franchise during the expansion and approval preparation of a new indication for Somatuline Depot (lanreotide).
Prior to his consulting career, Paul spent 17 years with Amgen and brings an extensive track record of success in Oncology. Paul was a results-driven marketing and sales executive known for his ability to penetrate new markets, launch blockbuster brands, build high performing sales teams, and drive sales results. His expertise spans both specialty and primary care markets in integrated health systems and traditional office-based segments. Paul served as U.S. Marketing Launch lead and Brand Director within Amgen’s Oncology franchise. He was a founding member of Amgen’s Bone Health Business Unit, partnering with Managed Markets, Government Affairs, and Healthcare Policy teams to ensure the successful performance of multiple therapeutics. Paul was also a member of Amgen’s Corporate Strategy team and led the launch of Amgen’s commercial entry into Latin America.
Paul earned both his Bachelor’s degree and Master of Business Administration from Bowling Green State University.
Vice President, Neuroscience Business Unit
Donald Pearl is responsible for building the neurology commercial structure in the U.S. as Ipsen builds upon its 20 years of clinical experience in the space and pursues a comprehensive and ambitious neurotoxin clinical study program.
Donald joins Ipsen from SkinMedica, an Allergan Company, where he was recently Vice President, International Sales and Marketing. His 25-year career also includes positions of increasing responsibility in neurology sales and marketing. His experience spans selling pharmaceuticals, surgical devices and topical skincare, leading U.S. and international sales and marketing teams, corporate account management, leading reimbursement policy and access teams and sales operations.
Donald holds a bachelors degree from Rutgers College and a Certificate in Healthcare Management from New York University. He is a retired U.S. Army Infantry Officer with experience at the Battalion, Brigade and Division levels.
David Cox, PhD
Vice President, Medical and Regulatory Affairs
Dr. Cox is responsible for leading medical affairs, post-marketing regulatory affairs, and health outcomes & economics research activities for Ipsen's portfolio in North America. He has spent the majority of his career in global and local medical affairs and clinical development roles working at Eisai Pharmaceuticals, Bristol-Myers Squibb, Galderma Pharmaceuticals and Precept Medical Communications.
Most recently, Dr. Cox was the Americas Medical Strategy Lead at Eisai, managing medical directors and MSL teams, and leading the medical affairs strategy for the company’s oncology portfolio in North America and South America. His therapeutic area experience also includes metabolics/cardiovascular and neurology and he has had extensive involvement with product launches, business development, orphan diseases, and medical affairs team building/planning.
A biologic chemist by training, Dr. Cox earned his BA from Rutgers University and his PhD from the University of Pennsylvania, where he received the Henry Miller Thesis Award for Most Outstanding Doctoral Dissertation for his graduate studies.
Vice President, Value and Access
Ron Graybill is an accomplished managed-markets professional with expertise in consultative sales, marketing, pricing strategies, product revitalization and lifecycle management.
Most recently, Ron was Vice President, Managed Markets at Mylan Specialty where he provided strategic direction to senior executives to ensure long-term growth and profitability for Mylan’s branded, generic, and biosimilar businesses. He has also held positions at Bayer Healthcare, Novartis, and Hoechst-Roussel Pharmaceuticals, Inc.
Ron earned his Master of Business Administration degree in Finance from Farleigh Dickinson and an undergraduate degree in economics from Rutgers, The State University of New Jersey-New Brunswick.
Vice President Business Analytics, Commercial Strategy & Operations
Paul Saatsoglou will be responsible for leading the Business Analytics & Sales Operations functions, as well as providing insight and direction around critical operational improvement, strategic projects and process improvement methodologies.
Paul possesses over 30 years of experience and has held roles with both US & Global scope within major pharmaceutical organizations. His experience spans both leadership of business analytics teams in support of marketing, sales and business development, US and global, as well as content expertise in marketing analytics and forecasting related to oncology product launches. He also has expertise in marketing metrics and sales operations.
Paul earned his Master’s degree in Statistics/Operations Research from the Wharton School, University of Pennsylvania and an undergraduate degree in Physics from Franklin & Marshall College.
General Manager, Canada
Lyndal Walker brings to Ipsen 25 years of experience in the pharmaceutical and medical device industry in Canada, as well as internationally. Lyndal will build and lead the Ipsen team in Canada to deliver our therapies to physicians and improve the lives of patients.
Lyndal started her pharmaceutical industry career at Eli Lilly, holding a number of progressively senior positions and leadership roles within Lilly’s specialty product business unit. Lyndal has developed and led global marketing teams, marketed specialty products and has a number of years of experience in oncology and interventional cardiology. In 2005 she was appointed as the General Manager for Abraxis Bioscience in Canada. Most recently, she served at Fresenius Kabi as the new company integration lead, in charge of two critical operational effectiveness projects for the organization in Canada.
Lyndal earned her diploma in Nursing from The Mater, Brisbane, Australia and a science degree (BScN – health promotion) from the University of Windsor, Ontario, Canada.
Chief Financial Officer, Ipsen North America
Harry brings 30 years of business experience and a keen understanding of the pharmaceutical industry to his role as Chief Financial Officer for Ipsen Biopharmaceuticals, Inc. Previously, Harry held Chief Financial Officer positions at Cormedix and Mylan Specialty and was a key contributor to Mylan Specialty’s period of intense growth between 2010 and 2013. Harry also previously oversaw Finance and Finance Operations for the Sterile Business Unit as a VP of Finance at Catalent Pharma Solutions.
Harry spent 13 years at Bayer Healthcare Pharmaceuticals in the roles of VP Business Planning and Administration, Controller, and Executive Director for Managed Markets. At Bayer, he implemented an efficient Global Business Unit model for a $2 billion business unit as well as spearheaded strategic and operative planning, portfolio analysis, business development support, and integration.
Harry is a Certified Public Accountant with a Bachelors degree in Accounting from Pace University and a Masters of Business Administration from Lehigh University.
Vice President & NA General Counsel
Jennifer Benenson brings more than 20 years of experience as counsel in the pharmaceutical industry to her role as Vice President and North American General Counsel. She is responsible for managing the delivery of all legal services to Ipsen business units in NA, with a primary focus on investigations, litigation, product life cycle issues, pricing, employment matters and support of Ipsen’s management committee on strategic matters.
Prior to joining Ipsen in 2011, Jennifer served as Vice President and General Counsel at Daiichi Pharmaceutical Corporation for 10 years, Vice President of Legal Affairs at Dr. Reddy’s Laboratories and was Vice President, Legal at Medco Health Solutions working in research and personalized medicine.
Jennifer earned her undergraduate degree in political science from Brown University and her JD from Columbia University School of Law.
Vice President, Ethics & Compliance- North America
Ed Leskauskas brings to Ipsen a wealth of compliance knowledge and experience in addition to expertise in business strategy, change management, and process reengineering. He is responsible for directing all ethics & compliance activities across North America.
He most recently held the role of Director, U.S. Pharmaceuticals Compliance (USP) and Ethics at Bristol-Myers Squibb Company where he was responsible for providing compliance guidance to the USP business and brand teams, directing compliance integration of acquired entities, leading the implementation of the BMS Corporate Integrity Agreement and managing compliance risk identification and mitigation. Ed also leverages 10 years of experience as a consultant in the Pharmaceutical and Consumer industries, focused on initiatives such as process reengineering, systems implementation, merchandising, logistics, and portfolio management.
Ed holds a Master of Business Administration degree from The Mason School of Business at The College of William and Mary and earned his undergraduate degree from Drew University.
Vice President, Human Resources
Christopher Cozic will actively build the Human Resources team, capabilities and processes to drive Ipsen growth in North America. He will also serve on the North American Management Committee as lead for North American Human Resource functions.
With more than 15 years of Human Resource leadership experience across the pharmaceutical, telecommunication and consulting industries, Christopher brings expertise in talent acquisition, change management, process and systems development, leadership development and the creation of global corporate infrastructure. Christopher joins Ipsen from Eisai. He has also worked at Norvergence Inc. and the Allegis Group.
Christopher holds a B.A. degree in English from Quinnipiac University in Hamden, Connecticut. He is currently a member of the Society for Human Resource Management. Christopher is also a certified executive coach through The Institute for Professional Excellence in Coaching (IPEC).
Head, North America Government Affairs & Policy
Bob joins Ipsen as Head, North America, Government Affairs and Policy, responsible for leading strategy development and representing Ipsen Biopharmaceuticals, Ipsen Bioscience and Ipsen Canada. He will be liaising with government officials, public agencies, industry organizations and patient/professional organizations regarding legislation and policy issues.
Prior to joining Ipsen, Bob was at Sanofi for seven years, most recently serving as the Head of Public Affairs Competitive Intelligence where he created a novel competitive intelligence group for North American public affairs activities. While at Sanofi, he also led the public policy function for all of Sanofi’s U.S. and Canadian functional units and subsidiaries covering prescription drugs, R&D, consumer products and animal health.
Previous to Sanofi, Bob worked for Eisai for twelve years in roles of increasing responsibility. He served as head of U.S. federal/state government relations and public policy. Bob also led regulatory strategies and government stakeholder engagement for all ex-U.S. jurisdictions in North and South America—Canada, Brazil, Mexico, etc. as the Senior Director, Strategic and Public Policy for the Americas, New Markets Group for Eisai.
Bob has an MBA from Columbia University Graduate School of Business and a Bachelor of Arts in Business Economics from Canisius College.